Review
Biochemistry & Molecular Biology
Elisabetta Bretto, Davide Giuseppe Ribaldone, Gian Paolo Caviglia, Giorgio Maria Saracco, Elisabetta Bugianesi, Simone Frara
Summary: Inflammatory bowel disease (IBD) refers to a group of chronic, relapsing inflammatory disorders of the gastrointestinal tract, including Crohn's disease and ulcerative colitis. The global incidence and prevalence of IBD have been increasing, and although the specific causes are still unknown, immunological, genetic, and environmental factors are believed to play a role. The development of biologic therapies in the past few decades has greatly improved the treatment of IBD, but there is still no definitive cure and some patients may not respond well to available therapies. However, emerging therapies targeting new pathogenic mechanisms show promising efficacy and safety in early clinical trials, and their potential significance in shaping future treatment options is being emphasized.
Review
Gastroenterology & Hepatology
Klaus R. Herrlinger, Eduard F. Stange
Summary: This review examines the current guidelines for the treatment of inflammatory bowel disease (IBD) and suggests personalized treatment options based on individual clinical cases. The analysis of relevant literature suggests that combined use of drugs such as infliximab and azathioprine can improve treatment outcomes for Crohn's disease and ulcerative colitis. In cases of steroid-refractory ulcerative colitis, the preference should be given to infliximab plus azathioprine or upadacitinib.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Medicine, General & Internal
Claudia Herrera-deGuise, Xavier Serra-Ruiz, Ernesto Lastiri, Natalia Borruel
Summary: Inflammatory bowel disease (IBD) is a chronic immune-mediated condition of the gastrointestinal tract. New monoclonal antibodies targeting specific cytokines have been dominant in IBD treatment, but many patients experience incomplete response or adverse events. Janus kinase (JAK) is important in modulating signal transduction pathways involved in gastrointestinal inflammation and may be a promising target for IBD treatment.
FRONTIERS IN MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Hua-Min Zhang, Shuo Yuan, Huan Meng, Xiao-Ting Hou, Jiao Li, Jia-Chen Xue, You Li, Qi Wang, Ji-Xing Nan, Xue-Jun Jin, Qing-Gao Zhang
Summary: Inflammatory bowel disease (IBD) is a chronic, relapsing disease that greatly affects patients' quality of life. Stem cell therapy has shown potential to improve the clinical disease activity of patients with refractory IBD when conventional treatments are not effective, but its safety and long-term efficacy need further evaluation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Michelle Temby, Theresa L. Boye, Jacqueline Hoang, Ole H. Nielsen, John Gubatan
Summary: This article reviews the role of kinase signaling pathways in colitis-associated colon cancer, including MAPK, CDK, autophagy-activated kinases, JAK-STAT, and other kinases. It also discusses the involvement of JAK-STAT signaling in the pathogenesis of inflammatory bowel disease (IBD) and the potential use of JAK inhibitors for treating IBD.
Review
Gastroenterology & Hepatology
Shubha Bhat, Benjamin Click, Miguel Regueiro
Summary: The recent approval of new medications and updated safety information has changed the treatment landscape of inflammatory bowel disease (IBD). This review examines the safety data of monoclonal antibodies and small molecules for IBD, focusing on recently FDA-approved therapies, and proposes risk stratification and assessment considerations for IBD treatment.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Medicine, General & Internal
Marie Villumsen, Astrid Blicher Schelde, Espen Jimenez-Solem, Tine Jess, Kristine Hojgaard Allin
Summary: Patients with inflammatory bowel disease (IBD) and type 2 diabetes treated with GLP-1 based therapies had a lower risk of adverse clinical events compared to those treated with other antidiabetics. This suggests that GLP-1 based therapies may improve the disease course of IBD.
Review
Biochemistry & Molecular Biology
Monica State, Lucian Negreanu
Summary: There is a lack of clear definitions and guidelines for the response criteria and treatment optimization in advanced therapies for inflammatory bowel disease, leading to inconsistent treatment strategies and premature abandonment of effective therapies.
Review
Biochemistry & Molecular Biology
Vishal Khatri, Ramaswamy Kalyanasundaram
Summary: This review focuses on the association between IBD and gut inflammasome, as well as recent advances in research and therapeutic strategies for IBD, discussing inflammasomes and their components, outcomes from experimental animals and human studies, inflammasome inhibitors, and developments in inflammasome-targeted therapies for IBD.
Review
Biochemistry & Molecular Biology
HyunTaek Jung, Jae Seok Kim, Keum Hwa Lee, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Sung Hwi Hong, Dong Keon Yon, Seung Won Lee, Min Seo Kim, Paul Wasuwanich, Wikrom Karnsakul, Jae Il Shin, Andreas Kronbichler
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people. Recent studies have shown that microRNAs (miRNAs) play an important role in the pathogenesis, diagnosis, and treatment of IBD.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Uma Mahadevan, Millie D. Long, Sunanda Kane, Abhik Roy, Marla C. Dubinsky, Bruce E. Sands, Russell D. Cohen, Christina D. Chambers, William J. Sandborn
Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.
Article
Pharmacology & Pharmacy
Vipul Yadav, Aileen House, Silvia Matiz, Laura E. McCoubrey, Kimberly A. Bettano, Leena Bhave, Meiyao Wang, Peter Fan, Siqun Zhou, Janice D. Woodhouse, Eirini Poimenidou, Liu Dou, Abdul W. Basit, Lily Y. Moy, Robert Saklatvala, Laxminarayan G. Hegde, Hongshi Yu
Summary: In this study, the feasibility of ileocolonic-targeted delivery of a pan-JAK inhibitor, tofacitinib, was explored and it was found that ileocolonic-targeted capsules significantly decreased systemic drug exposure and increased colonic tissue exposure compared to gastric release capsules and an oral solution. In a rat model of colonic inflammation, targeted tofacitinib capsules also significantly reduced concentrations of proinflammatory interleukin 6 in colonic tissue.
Article
Medicine, General & Internal
Silvia Salvatori, Francesco Baldassarre, Michelangela Mossa, Giovanni Monteleone
Summary: Long COVID is common in patients with inflammatory bowel diseases (IBD), with fatigue being the most frequent symptom. It does not influence the frequency of IBD relapses, but is more prevalent in female patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Gastroenterology & Hepatology
Thomas M. Goodsall, Tran M. Nguyen, Claire E. Parker, Christopher Ma, Jane M. Andrews, Vipul Jairath, Robert Bryant
Summary: The study systematically identified ultrasound scoring indices for assessing inflammatory bowel disease activity, with common components including bowel wall thickness, colour Doppler imaging, and bowel wall stratification. The correlation between ultrasound indices and reference standards, as well as sensitivity, specificity, accuracy, and other properties, varied within certain ranges. However, reliability and responsiveness data were limited, and most studies were rated with unclear or high risk of bias.
JOURNAL OF CROHNS & COLITIS
(2021)
Review
Medicine, General & Internal
Katarzyna Akutko, Andrzej Stawarski
Summary: Inflammatory bowel diseases (IBD) are chronic inflammatory diseases of the digestive tract with periods of remission and relapses. The etiopathogenesis is not fully understood, leading to only symptomatic treatment. There is a constant need to search for new high safety profile therapies for IBD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Iago Rodriguez-Lago, Jesus Castro-Poceiro, Agnes Fernandez-Clotet, Francisco Mesonero, Antonio Lopez-Sanroman, Alicia Lopez-Garcia, Lucia Marquez, Ariadna Clos-Parals, Fiorella Canete, Miren Vicuna, Oscar Nantes, Olga Merino, Virginia Matallana, Jordi Gordillo, Ainara Elorza, Raquel Vicente, Maria Jose Casanova, Rocio Ferreiro-Iglesias, Pablo Perez-Galindo, Jose Manuel Benitez, Carlos Taxonera, Maria Jose Garcia, Eduardo Martin, Urko Aguirre, Javier P. Gisbert
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2020)
Article
Gastroenterology & Hepatology
Marisa Iborra, Belen Beltran, Agnes Fernandez-Clotet, Eva Iglesias-Flores, Pablo Navarro, Montserrat Rivero, Ana Gutierrez, Monica Sierra-Ausin, Francisco Mesonero, Rocio Ferreiro-Iglesias, Joaquin Hinojosa, Xavier Calvet, Beatriz Sicilia, Carlos Gonzalez-Munoza, Beatriz Antolin, Maria Gonzalez-Vivo, Ana Y. Carbajo, Santiago Garcia-Lopez, Albert Martin-Cardona, Gerard Suris, Maria Dolores Martin-Arranz, Ruth de Francisco, Fiorella Canete, Eugeni Domenech, Pilar Nos
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2020)
Article
Gastroenterology & Hepatology
Maria Chaparro, Ana Garre, Francisco Mesonero, Cristina Rodriguez, Manuel Barreiro-de Acosta, Jesus Martinez-Cadilla, Maria T. Arroyo, Noemi Mancenido, Monica Sierra-Ausin, Isabel Vera-Mendoza, Maria Jose Casanova, Pilar Nos, Carlos Gonzalez-Munoza, Teresa Martinez, Maia Bosca-Watts, Margalida Calafat, David Busquets, Eva Girona, Jordina Llao, Maria Dolores Martin-Arranz, Marta Piqueras, Laura Ramos, Gerard Suris, Fernando Bermejo, Ana Y. Carbajo, Diego Casas-Deza, Agnes Fernandez-Clotet, Maria J. Garcia, Daniel Ginard, Ana Gutierrez-Casbas, Luis Hernandez, Alfredo J. Lucendo, Lucia Marquez, Olga Merino-Ochoa, Francisco J. Rancel, Carlos Taxonera, Antonio Lopez Sanroman, Saioa Rubio, Eugeni Domenech, Javier P. Gisbert
Summary: The study findings indicate that tofacitinib is effective and safe in treating active ulcerative colitis. However, a significant proportion of patients discontinue the drug over time, mainly due to primary failure.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Marisol Veny, Alba Garrido-Trigo, Ana M. Corraliza, Maria C. Masamunt, Helena Bassolas-Molina, Miriam Esteller, Montserrat Arroyes, Eva Tristan, Agnes Fernandez-Clotet, Ingrid Ordas, Elena Ricart, Maria Esteve, Julian Panes, Azucena Salas
Summary: The study found that while vedolizumab and anti-TNF target different receptors, they induce remarkably similar effects. Additionally, vedolizumab's unique mechanism of action relies on blocking intestinal trafficking of alpha 4 beta 7 T cells.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Maria Chaparro, Ana Garre, Marisa Iborra, Monica Sierra-Ausin, Manuel Barreiro-de Acosta, Agnes Fernandez-Clotet, Luisa de Castro, Maia Bosca-Watts, Maria Jose Casanova, Alicia Lopez-Garcia, Rufo Lorente, Cristina Rodriguez, Ana Y. Carbajo, Maria Teresa Arroyo, Ana Gutierrez, Joaquin Hinojosa, Teresa Martinez-Perez, Albert Villoria, Fernando Bermejo, David Busquets, Blau Camps, Fiorella Canete, Noemi Mancenido, David Monfort, Merce Navarro-Llavat, Jose Lazaro Perez-Calle, Laura Ramos, Montserrat Rivero, Teresa Angueira, Patricia Camo Monterde, Daniel Carpio, Irene Garcia-de-la-Filia, Carlos Gonzalez-Munoza, Luis Hernandez, Jose M. Huguet, Victor J. Morales, Beatriz Sicilia, Pablo Vega, Isabel Vera, Yamile Zabana, Pilar Nos, Patricia Suarez Alvarez, Cristina Calvino-Suarez, Elena Ricart, Vicent Hernandez, Miguel Minguez, Lucia Marquez, Daniel Hervias Cruz, Saioa Rubio Iturria, Jesus Barrio, Carla Gargallo-Puyuelo, Ruben Frances, Esther Hinojosa, Maria del Moral, Xavier Calvet, Alicia Algaba, Xavier Aldeguer, Jordi Guardiola, Miriam Manosa, Ramon Pajares, Marta Piqueras, Orlando Garcia-Bosch, Pilar Lopez Serrano, Beatriz Castro, Alfredo J. Lucendo, Miguel Montoro, Elena Castro Ortiz, Francisco Mesonero, Esther Garcia-Planella, David A. Fuentes, Inmaculada Bort, Pedro Delgado-Guillena, Lara Arias, Agueda Iglesias, Marta Calvo, Maria Esteve, Eugeni Domenech, Javier P. Gisbert
Summary: Ustekinumab has shown durability and effectiveness in the treatment of ulcerative colitis, even in real life situations. Higher levels of serum C-reactive protein were associated with a lower probability of achieving remission. In the short term, 53% of patients showed a positive response to the treatment.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Empar Sainz, Yamile Zabana, Isabel Miguel, Agnes Fernandez-Clotet, Belen Beltran, Laura Nunez, Maria Jose Garcia, Maria Dolores Martin-Arranz, Eva Iglesias, Fiorella Canete, Ana Gutierrez, Marta Piqueras, Isabel Perez-Martinez, Luis Bujanda, Iago Rodriguez-Lago, Maria Jose Casanova, Pablo Navarro, Raquel Vicente, Olga Merino, Alicia Algaba, Cristina Rodriguez, Jose M. Huguet, Fernando Fernandez-Banares, Eugeni Domenech, Maria Esteve
Summary: This study investigates the clinical characteristics, therapeutic requirements, and complications associated with upper gastrointestinal involvement in patients with Crohn's disease. The findings indicate that upper gastrointestinal involvement is independently associated with extensive involvement, strictures, chronic iron deficiency anemia, and the use of second-line biologics. Patients with upper gastrointestinal involvement have a shorter median stricture-free time compared to controls. Additionally, those with isolated upper gastrointestinal involvement more frequently exhibit localized disease and undergo more endoscopic stricture dilations.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Agnes Fernandez-Clotet, Victor Sapena, Nunzia Capozzi, Sonia Rodriguez, Maria-Carme Masamunt, Elena Ricart, Ingrid Ordas, Julian Panes, Jordi Rimola
Summary: Simplified Magnetic Resonance Index of Activity (sMaRIA) calculated with or without contrast-enhanced sequences accurately classified the response to biologic drugs in patients with Crohn's disease.
EUROPEAN RADIOLOGY
(2022)
Article
Medicine, General & Internal
Maria Jose Garcia, Montserrat Rivero, Jose Miranda-Bautista, Iria Baston-Rey, Francisco Mesonero, Eduardo Leo-Carnerero, Diego Casas-Deza, Carmen Cagigas Fernandez, Albert Martin-Cardona, Ismael El Hajra, Nerea Hernandez-Aretxabaleta, Isabel Perez-Martinez, Esteban Fuentes-Valenzuela, Nuria Jimenez, Cristina Rubin de Celix, Ana Gutierrez, Cristina Suarez Ferrer, Jose Maria Huguet, Agnes Fernandez-Clotet, Maria Gonzalez-Vivo, Blanca Del Val, Jesus Castro-Poceiro, Luigi Melcarne, Carmen Duenas, Marta Izquierdo, David Monfort, Abdel Bouhmidi, Patricia Ramirez De la Piscina, Eva Romero, Gema Molina, Jaime Zorrilla, Cristina Calvino-Suarez, Eugenia Sanchez, Andrea Nunez, Olivia Sierra, Beatriz Castro, Yamile Zabana, Irene Gonzalez-Partida, Saioa De la Maza, Andres Castano, Rodrigo Najera-Munoz, Luis Sanchez-Guillen, Micaela Riat Castro, Jose Luis Rueda, Jose Manuel Benitez, Pedro Delgado-Guillena, Carlos Tardillo, Elena Pena, Santiago Frago-Larramona, Maria Carmen Rodriguez-Grau, Rocio Plaza, Pablo Perez-Galindo, Jesus Martinez-Cadilla, Luis Menchen, Manuel Barreiro-De Acosta, Ruben Sanchez-Aldehuelo, Maria Dolores De la Cruz, Luis Javier Lamuela, Ignacio Marin, Laura Nieto-Garcia, Antonio Lopez-San Roman, Jose Manuel Herrera, Maria Chaparro, Javier P. Gisbert
Summary: The study results suggest that preoperative administration of biologics in IBD patients does not seem to be a risk factor for overall postoperative complications, although it may increase the risk of postoperative infections.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Miriam Manosa, Agnes Fernandez-Clotet, Pilar Nos, Maria Dolores Martin-Arranz, Noemi Mancenido, Ana Carbajo, Esther Hinojosa, Alejandro Hernandez-Camba, Roser Munoz-Perez, Maia Bosca-Watts, Marta Calvo, Monica Sierra-Ausin, Eugenia Sanchez-Rodriguez, Manuel Barreiro-de Acosta, Alejandro Nunez-Alonso, Yamile Zabana, Lucia Marquez, Javier P. Gisbert, Jordi Guardiola, Empar Sainz, Pedro Delgado-Guillena, David Busquets, Manuel van Domselaar, Eva Girona, Rufo Lorentea, Diego Casas-Deza, Jose M. Huguet, Sergio Maestro, M. Jose Cabello, Jesus Castro, Marisa Iborra, Fiorella Canete, Margalida Calafat, Eugeni Domenech
Summary: This study found that ustekinumab and vedolizumab are effective in preventing postoperative recurrence in high-risk Crohn's disease patients. However, further controlled trials comparing these drugs with conventional therapies are needed.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Medicine, General & Internal
Maria Gonzalez-Vivo, Minna K. Lund Tiirikainen, Montserrat Andreu, Agnes Fernandez-Clotet, Alicia Lopez-Garcia, Francisca Murciano Gonzalo, Lourdes Abril Rodriguez, Carmen de Jesus-Gil, Ester Ruiz-Romeu, Lidia Sans-de San Nicolas, Lluis F. Santamaria-Babi, Lucia Marquez-Mosquera
Summary: Baseline circulating CD8 (+) alpha(4)beta(+)(7) memory T cells could serve as an early predictor of remission in patients with ulcerative colitis, helping to select a subset of responders.
FRONTIERS IN MEDICINE
(2022)
Article
Health Care Sciences & Services
Carlo Biffi, Pietro Salvagnini, Nhan Ngo Dinh, Cesare Hassan, Prateek Sharma, Andrea Cherubini
Summary: In this study, a novel intelligent medical device was developed to operate seamlessly in real-time using conventional white light endoscopy video stream without the need for virtual chromoendoscopy. The device has the potential to support non-expert endoscopists in systematically reaching the performance level of expert endoscopists in optical characterization.
NPJ DIGITAL MEDICINE
(2022)
Correction
Health Care Sciences & Services
Carlo Biffi, Pietro Salvagnini, Nhan Ngo Dinh, Cesare Hassan, Prateek Sharma, Andrea Cherubini
NPJ DIGITAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Carlo Reverberi, Tommaso Rigon, Aldo Solari, Cesare Hassan, Paolo Cherubini, Andrea Cherubini
Summary: Artificial Intelligence (AI) systems provide valuable support in decision-making, especially in the medical field. The interaction between humans and AI, known as human-AI collaboration, can achieve better outcomes by integrating the opinions of both parties.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, General & Internal
Cristina Romero-Mascarell, Gloria Fernandez-Esparrach, Cristina Rodriguez-De Miguel, Maria Carme Masamunt, Sonia Rodriguez, Jordi Rimola, Miguel Urpi, Gherzon Simon Casanova, Ingrid Ordas, Elena Ricart, Berta Caballol, Agnes Fernandez-Clotet, Julia Panes, Josep Llach, Begona Gonzalez-Suarez
Summary: The study found a good correlation between fecal calprotectin (FC) levels and small bowel lesions in patients with established or suspected Crohn's disease. The ideal cutoff value for FC was found to be higher than previously reported, indicating the need for further research to establish definitive FC cutoff levels.
Article
Gastroenterology & Hepatology
Manuel Barreiro-de Acosta, Agnes Fernandez-Clotet, Francisco Mesonero, Francisco Javier Garcia-Alonso, Maria Jose Casanova, Margarita Fernandez-de la Varga, Fiorella Canete, Luisa de Castro, Ana Gutierrez, Beatriz Sicilia, Victoria Cano, Olga Merino, Ruth de Francisco, Irene Gonzalez-Partida, Gerard Suris, Leyanira Torrealba, Rocio Ferreiro-Iglesias, Beatriz Castro, Lucia Marquez, Ana Sobrino, Ainara Elorza, Xavier Calvet, Pilar Varela, Raquel Vicente, Luis Bujanda, Laura Lario, Noemi Mancenido, Mariana F. Garcia-Sepulcre, Eva Iglesias, Cristina Rodriguez, Marta Piqueras, Juan Angel Ferrer Rosique, Alfredo J. Lucendo, Olga Benitez, Melody Garcia, David Olivares, Carlos Gonzalez-Munoza, Beatriz Lopez-Cauce, Victor Jair Morales Alvarado, Katerina Spicakova, Alicia Brotons, Fernando Bermejo, Pedro Almela, Nahia Ispizua, Pau Gilabert, Carlos Tardillo, Fernando Munoz, Pablo Navarro, Rosa Eva Madrigal Dominguez, Pau Sendra, Esther Hinojosa, Empar Sainz, Maria Dolores Martin-Arranz, Daniel Carpio, Elena Ricart, Berta Caballol, Laura Nunez, Jesus Barrio, Javier P. Gisbert, Marisa Iborra, Margalida Calafat, Vicent Hernandez, Roser Munoz Perez, Jose Luis Cabriada, Eugeni Domenech, Iago Rodriguez-Lago
Summary: This study evaluated the effectiveness of biologic agents in Crohn's disease complicated with internal fistulizing disease. It found that biologic therapy is beneficial for approximately three-quarters of patients, achieving a fistula closure rate of 24%, but around one-third of patients still require surgery. Patient- and lesion-related factors can identify patients who will obtain more benefit from these drugs.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)